Avidity Biosciences. has been granted a patent for compositions and pharmaceutical formulations that combine a binding moiety with a modified polynucleic acid molecule and a polymer. The patent also outlines methods for treating diseases using these formulations. GlobalData’s report on Avidity Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Avidity Biosciences, Nanoparticle drug conjugates was a key innovation area identified from patents. Avidity Biosciences's grant share as of June 2024 was 22%. Grant share is based on the ratio of number of grants to total number of patents.
Binding moiety conjugated to modified polynucleic acid and polymer
The granted patent US12006499B2 outlines a novel compound characterized by a specific chemical structure, referred to as Formula (II). The claims detail various configurations and modifications of this compound, including the presence of pharmaceutically acceptable salts or solvates. Notably, the claims specify the substituents R1, R2, and R3, which can vary in structure, including options such as —OCH2C(-O)NR7R7 for R1, where R7 can be hydrogen or C1-C3 alkyl groups. Additionally, the claims describe the potential for R2 to be isopropyl or to form a heterocycloalkyl structure when combined with a nitrogen atom.
Further claims elaborate on the structural components of the compound, including the nature of Ring G and the specific configuration of substituents. For instance, the claims indicate that X can be oxygen, and R3 can be a 4,4'-dimethoxytrityl (DMT) group. The patent emphasizes the versatility of the compound's structure, allowing for various chemical modifications that may enhance its pharmaceutical properties. Overall, the claims provide a comprehensive framework for the compound's potential applications in medicinal chemistry, highlighting its structural diversity and the implications for further research and development in therapeutic contexts.
To know more about GlobalData’s detailed insights on Avidity Biosciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
